与辅助治疗疗效相关的微生物标志物探索性研究
一项基于瘤内微生物组特征及其功能靶点预测全胃肠道癌症患者新辅助治疗疗效与预后的单中心探索性研究。
Digestive system malignancies are among the most common types of cancers in China, primarily including esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, and colorectal cancer. According to the 2024 National Cancer Registry data released by the National Cancer Center of China (covering a population of 523 million), digestive system tumors (including colorectal, liver, gastric, and esophageal cancers) account for 28.49% of all new cancer cases and 31.77% of total cancer-related deaths in the country. Among these, the incidence and mortality burdens of gastric, esophageal, and liver cancers are significantly higher than the global average. Most patients are diagnosed at an advanced stage, with a five-year survival rate below 30%. This highlights that digestive system malignancies represent a major public health challenge in China, necessitating in-depth studies on their pathogenesis and the development of novel prevention and treatment strategies.
At present, radical surgical resection remains the only potentially curative option for digestive system cancers. However, for patients with locally advanced or late-stage disease, surgery alone yields limited efficacy. In recent years, chemotherapy-based neoadjuvant therapy has been increasingly applied in clinical practice to improve R0 resection rates and overall survival [4-6]. Nevertheless, current studies show that the response rate to neoadjuvant therapy remains modest, and there is a lack of precise strategies for identifying therapy-sensitive patient subgroups, resulting in a limited proportion of patients who truly benefit.
The gut microbiota, as an essential component of the human microecosystem, plays a critical role in tumor initiation, progression, metastasis, and therapeutic response. Given the anatomic location of digestive system cancers, the gut microbiota-being a major source of intratumoral microorganisms-interacts closely with the tumor microenvironment. Studies have revealed marked differences in the gut microbial composition between pancreatic cancer patients and healthy individuals, characterized by a significant reduction in short-chain fatty acid (SCFA)-producing bacteria and enrichment of inflammation-associated species. Furthermore, gut-derived microbes within pancreatic tumors are closely associated with immune microenvironment remodeling and gemcitabine resistance.
Similarly, gastric cancer patients exhibit distinct microbial profiles in both gastric fluid and tumor tissue compared with healthy controls-for instance, Helicobacter pylori enrichment-which may influence both tumorigenesis and neoadjuvant treatment efficacy. In colorectal cancer, Fusobacterium nucleatum and Peptostreptococcus anaerobius are significantly enriched in tumors resistant to immunotherapy, suggesting a key role of gut microbiota in treatment resistance. In hepatocellular carcinoma, intratumoral microbial subtypes are closely linked to tumor progression, and Klebsiella pneumoniae has been shown to promote hepatocarcinogenesis.
However, many key microbial species and their mechanistic roles in shaping the tumor microenvironment of digestive system cancers remain poorly understood, limiting the further clinical application of strategies such as neoadjuvant therapy in these patients. Therefore, a deeper investigation into the microbial characteristics of digestive system tumors and their correlation with neoadjuvant therapeutic response is of great clinical significance, particularly for identifying microbiome-based biomarkers that predict therapeutic efficacy and enable the selection of optimal candidate populations.
In summary, we have designed a prospective exploratory study to investigate the microbial characteristics and functional targets of digestive system cancers, aiming to develop and preliminarily validate a predictive model for identifying patient subgroups likely to benefit from neoadjuvant therapy. This study seeks to discover microbiome-associated biomarkers predictive of treatment efficacy and to expand the clinical application scope of neoadjuvant therapy in digestive system malignancies.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Tianjin、中国
- Patients with esophageal, pancreatic, gastric, or colorectal cancer who are scheduled to receive neoadjuvant therapy
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with pancreatic, gastric, or colorectal cancer who are scheduled to receive neoadjuvant therapy
描述
Inclusion Criteria:
- Age ≥18 years and ≤80 years
- Pathologically confirmed diagnosis (via preoperative biopsy) of pancreatic cancer, gastric cancer, colorectal cancer, or esophageal cancer
- Imaging evaluation indicates borderline resectable or locally advanced disease, and the patient is scheduled to receive neoadjuvant therapy according to treatment guidelines
- Expected survival time > 3 months
- Hematologic function: neutrophil count > 1.5 × 10⁹/L
- Liver function:Total serum bilirubin ≤ 1.5 × upper limit of normal (ULN);ALT and AST ≤ 2 × ULN
- Renal function: serum creatinine ≤ 1.5 × ULN
- No severe cardiovascular or cerebrovascular comorbidities and no psychiatric disorders
Exclusion Criteria:
- Physically unfit to undergo neoadjuvant chemotherapy
- Local recurrence or distant metastasis occurring within 1 month after surgery
- Impaired vital organ function, including but not limited to: Heart failure (NYHA Class III-IV); Myocardial infarction within the past 6 months; Severe arrhythmia; Respiratory failure
- Presence of another primary malignancy diagnosed within the past 5 years
- Pregnant or breastfeeding
- Inability to complete follow-up
- Active infection
- Severe constipation or sudden changes in bowel habits within the past 3 months
- Significant changes in dietary habits (e.g., meat-vegetable balance, meal timing, or frequency) within the past 3 months
- Medication history within the past 3 months including:Use of NSAIDs, immunosuppressants, antibiotics, traditional Chinese medicine, probiotics, or corticosteroids for ≥1 week; Use of proton pump inhibitors (PPIs) for more than 1 week within 1 month prior to sampling
- Refusal to sign the informed consent form
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
胃癌
|
This study is observational and involves no interventions. |
|
结直肠癌
|
This study is observational and involves no interventions. |
|
胰腺癌
|
This study is observational and involves no interventions. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean fluorescence intensity of lipid raft staining in intratumoral immune cells measured by confocal immunofluorescence microscopy
大体时间:6 month
|
Lipid raft staining intensity will be assessed by confocal immunofluorescence using cholera toxin subunit B (CTB). Quantification will be performed using ImageJ software and reported as mean fluorescence intensity per cell, averaged across representative fields per tumor sample. |
6 month
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- bc20253994
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.